BeiGene - BGNE Operating profit EBITDA
The flagship drug Brukinsa enables BeiGene, Ltd. (BGNE) to rapidly capture market share while strengthening the business's patent protection. Diversification through an extensive portfolio of immunological agents mitigates risks. This EBITDA chart captures the operating cash flow, where the metric stands at 1349.96. This biotech leader is outperforming industry behemoths by leveraging its proprietary testing platform to reduce costs and accelerate drug development timelines.
BeiGene (BGNE) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
BGNE - Company Net Income|Net Profit Forecast BeiGene, Ltd.|BGNE - P/E Multiple|Projected Price to Earnings Ratio beigene.com|BGNE - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation BeiGene|BGNE - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BeiGene|BGNE - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months beigene.com|BGNE - Earnings growth in current year|Projected earnings per share growth rate for next year BeiGene, Ltd.
Summary company analytics:BGNE BeiGene Ltd
This indicator measures cash flow from operating activities before interest, taxes, depreciation, and amortization, allowing for an assessment of the actual efficiency of operational capital management. By analyzing the overall EBITDA of BeiGene, Ltd. (BGNE) through GURU.Markets tools, an investor can see the scaling dynamics of Brukinsa sales and the impact of the BeiGene, Ltd. (BGNE) innovative pipeline on the business's ability to generate cash during its global expansion phase.
Who BeiGene, Ltd. competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Profit before payment of interest, taxes and amortization ERAS (erasca.com)|Operating profit EBITDA DCTH (Delcath Systems)|Y-mAbs Therapeutics Inc (YMAB) - Profit before interest, taxes and amortization|Aura Bio - Operating profit EBITDA|Operating income before deduction of amortization Candel Therapeutics CADL|ARAY: Operating profit EBITDA|Operating profit before depreciation charges SELLAS Life Sciences Group SLS|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Citius Oncology Inc. CTOR|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|Protara Tx - Operating profit before amortization|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|Aadi Bioscience, Inc. (WHWK) - Profit before interest, taxes and amortization|TCRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CSBR (Champions Oncology)|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|CVM (CEL-SCI) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization OSTX|RADX (radiopharmtheranostics.com) - Company profit before taxes, interest and amortization|Operating profit EBITDA ARTV|adlainortye.com - Operating profit before amortization|Veru Pharma - Operating profit before deduction of amortization|Operating income before deduction of amortization Tempest Therapeutics Corp (TPST)|Xilio - Operating profit EBITDA|RENB: Profit before payment of interest, taxes and amortization|MURA: Operating profit EBITDA|Operating profit before depreciation charges Kairos Pharma KAPA|Profit before payment of interest, taxes and amortization OnKure Therapeutics, Inc.|Operating profit before amortization GDTC (CytoMed)|Operating profit EBITDA CRIS|APLM - Profit before interest, taxes and amortization|Operating profit EBITDA THAR (Tharimmune)|ADVB - Operating profit before deduction of amortization|Genprex, Inc - Operating profit EBITDA|CLDI - Operating profit EBITDA|Sunshine Biopharma, Inc. (SBFM) - Profit before payment of interest, taxes and amortization|Operating profit before amortization XBIO|SLRX (Salarius Pharmaceuticals, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Purple Biotech Ltd (PPBT)|Operating profit EBITDA AONC|CKPT - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|Income before deduction of interest, taxes and amortization ICAD|IKNA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NTBL (Notable Labs Ltd)|VIRX: Operating profit EBITDA|Operating profit before deduction of amortization MorphoSys Corporation|Operating profit before deduction of amortization NAYA|Operating profit EBITDA ascentage.com
